"Our client showed tremendous courage when he came to us," Sheller said. "He knew what Pfizer was doing was wrong and wanted to do something about it. Without him, and the egregious promotion discovered in the investigation of our case I don't believe the government's case against Pfizer on Zyvox could have been made."
Under the FCA, so-called "qui tam" whistleblower actions, a term derived from English Common Law meaning "he who sues on behalf of the king as well as himself," allow private citizens with knowledge of fraud to help the Government recover ill-gotten gains and additional civil penalties. The FCA allows the Government to collect up to three times the amount it was defrauded, in addition to civil penalties between $5,500 and $11,000 per false claim. Whistleblowers usually have received rewards representing 15 to 25 percent of qui tam recoveries, according to Sheller, whose law firm represents relators across the country.
Qui tam whistleblower cases recently settled by Sheller, P.C. have returned more than $1.5 billion to the U.S. and states' treasuries.
Sheller praised the work of Assistant U.S. Attorney Sara Bloom of the District of Massachusetts.
Sheller, McCormick and Pepper of Sheller, P.C. served as lead counsel in the case. Steven Brooks and Robert Hillman of Deutsch, Williams, Brooks, DeRensis & Holland, P.C., Boston, Massachusetts served as local counsel for the case.
U.S. ex. rel. Ronald Rainero v. Pfizer, Inc.;
District of Massachusetts, Case No: 07-CA-11728;
For more information about Sheller, P.C. and its attorneys, visit
|SOURCE Sheller, P.C. Law Firm|
Copyright©2009 PR Newswire.
All rights reserved